CA3145751A1 - Pyrrolo[2, 3-b]pyrazines as hpk1 inhibitor and the use thereof - Google Patents

Pyrrolo[2, 3-b]pyrazines as hpk1 inhibitor and the use thereof Download PDF

Info

Publication number
CA3145751A1
CA3145751A1 CA3145751A CA3145751A CA3145751A1 CA 3145751 A1 CA3145751 A1 CA 3145751A1 CA 3145751 A CA3145751 A CA 3145751A CA 3145751 A CA3145751 A CA 3145751A CA 3145751 A1 CA3145751 A1 CA 3145751A1
Authority
CA
Canada
Prior art keywords
8alkyl
heterocyclyl
cycloalkyl
methyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3145751A
Other languages
English (en)
French (fr)
Inventor
Jing Li
Zhiwei Wang
Sanjia XU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BeOne Medicines Ltd
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of CA3145751A1 publication Critical patent/CA3145751A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA3145751A 2019-07-04 2020-07-03 Pyrrolo[2, 3-b]pyrazines as hpk1 inhibitor and the use thereof Pending CA3145751A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2019094749 2019-07-04
CNPCT/CN2019/094749 2019-07-04
CNPCT/CN2019/123268 2019-12-05
CN2019123268 2019-12-05
CNPCT/CN2020/089498 2020-05-09
CN2020089498 2020-05-09
PCT/CN2020/100037 WO2021000925A1 (en) 2019-07-04 2020-07-03 PYRROLO [2, 3-b] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF

Publications (1)

Publication Number Publication Date
CA3145751A1 true CA3145751A1 (en) 2021-01-07

Family

ID=74100904

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3145751A Pending CA3145751A1 (en) 2019-07-04 2020-07-03 Pyrrolo[2, 3-b]pyrazines as hpk1 inhibitor and the use thereof

Country Status (14)

Country Link
US (1) US12454534B2 (https=)
EP (1) EP3994136A4 (https=)
JP (1) JP7579816B2 (https=)
KR (1) KR20220029690A (https=)
CN (3) CN114096536A (https=)
AU (1) AU2020299892A1 (https=)
BR (1) BR112022000019A2 (https=)
CA (1) CA3145751A1 (https=)
CO (1) CO2022001094A2 (https=)
IL (1) IL289553A (https=)
MX (1) MX2022000244A (https=)
TW (1) TWI848141B (https=)
WO (1) WO2021000925A1 (https=)
ZA (1) ZA202110732B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
TWI848141B (zh) 2019-07-04 2024-07-11 英屬開曼群島商百濟神州有限公司 及其用途
US12459958B2 (en) 2019-07-17 2025-11-04 Beone Medicines I Gmbh Tricyclic compounds as HPK1 inhibitor and the use thereof
CN114685490B (zh) * 2020-12-31 2025-03-28 南京再明医药有限公司 吡咯并吡啶类化合物及其应用
WO2022184152A1 (zh) * 2021-03-03 2022-09-09 劲方医药科技(上海)有限公司 稠环取代的六元杂环化合物及其制法和用途
CN115073472A (zh) * 2021-03-16 2022-09-20 江苏恒瑞医药股份有限公司 稠合二环类化合物、其制备方法及其在医药上的应用
WO2022199676A1 (zh) * 2021-03-26 2022-09-29 江苏恒瑞医药股份有限公司 稠合四环类化合物、其制备方法及其在医药上的应用
EP4341261A1 (en) * 2021-05-21 2024-03-27 Arcus Biosciences, Inc. Axl compounds
WO2022246179A1 (en) * 2021-05-21 2022-11-24 Arcus Biosciences, Inc. Axl inhibitor compounds
TW202321239A (zh) 2021-07-20 2023-06-01 瑞典商阿斯特捷利康公司 作為ｈｐｋ１抑制劑用於治療癌症之經取代的吡𠯤—２—甲醯胺
JP2024528722A (ja) * 2021-07-30 2024-07-30 ベイジーン リミテッド ＨＰＫ１分解誘導薬としてのピロロ［２，３－ｂ］ピラジン系の二官能性化合物及びその使用
WO2023151559A1 (zh) * 2022-02-08 2023-08-17 和径医药科技（上海）有限公司 杂环化合物、包含其的药物组合物及其抗肿瘤应用
CN116731029B (zh) * 2022-03-11 2026-01-02 石药集团中奇制药技术（石家庄）有限公司 一类并环化合物及其制备和应用
CN116925082A (zh) * 2022-04-24 2023-10-24 百济神州(苏州)生物科技有限公司 5H-吡咯并[2,3-b]吡嗪衍生物的多晶型形式，制备方法及其用途
WO2023207911A1 (zh) * 2022-04-24 2023-11-02 上海医药集团股份有限公司 一种双环杂环化合物、药物组合物和应用
WO2023207894A1 (en) * 2022-04-24 2023-11-02 Beigene , Ltd. POLYMORPH FORMS OF A 5H-PYRROLO [2, 3-b] PYRAZINE DERIVATIVE, METHODS OF PREPARATION, AND USES THEREFORE
AR129722A1 (es) 2022-06-28 2024-09-18 Arcus Biosciences Inc Compuestos inhibidores de axl

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942532A (en) 1997-09-05 1999-08-24 Ortho Pharmaceutical Corporation 2-substituted phenyl-benzimidazole antibacterial agents
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
WO2006015123A1 (en) 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
CA2573573A1 (en) * 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US7709645B2 (en) 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
WO2006058120A1 (en) 2004-11-22 2006-06-01 Vertex Pharmaceuticals Incorporated Bicyclic inhibitors or rho kinase
US20070087988A1 (en) 2005-09-30 2007-04-19 New York University Hematopoietic progenitor kinase 1 for modulation of an immune response
WO2010049173A1 (en) 2008-10-31 2010-05-06 Cenix Bioscience Gmbh Use of inhibitors of host kinases for the treatment of infectious diseases
JP6086326B2 (ja) 2010-05-24 2017-03-01 ユニヴァーシティー オブ ロチェスター 二環式ヘテロアリールキナーゼ阻害剤および使用方法
CN101851237B (zh) 2010-06-18 2012-10-17 南方医科大学 一种螺环化合物及其制备方法和应用
JP2012012332A (ja) 2010-06-30 2012-01-19 Dainippon Sumitomo Pharma Co Ltd 新規アザインドール誘導体
SG11201408816QA (en) 2012-07-03 2015-03-30 Aurigene Discovery Tech Ltd 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS
CN104884059B (zh) 2012-11-30 2018-08-10 罗切斯特大学 用于hiv/aids治疗的混合谱系激酶抑制剂
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
CN104513253A (zh) 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
CN105777756B (zh) 2014-07-02 2019-03-01 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
KR101660863B1 (ko) 2015-04-03 2016-09-28 주식회사 녹십자 IKKε 및 TBK1 억제제로서의 7-아자인돌 또는 4,7-다이아자인돌 유도체 및 이를 포함하는 약학적 조성물
WO2016164641A1 (en) * 2015-04-08 2016-10-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
MA42456B1 (fr) 2015-06-25 2021-06-30 Univ Health Network Inhibiteurs de hpk1 et leurs procédés d'utilisation
CN106336413B (zh) * 2015-07-09 2021-04-20 广东东阳光药业有限公司 作为jak抑制剂的化合物及其用途
CN106432246B (zh) 2015-08-05 2020-07-07 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
GB201517263D0 (en) 2015-09-30 2015-11-11 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
CN115819417A (zh) 2016-09-09 2023-03-21 因赛特公司 作为hpk1调节剂的吡唑并吡啶衍生物及其用于治疗癌症的用途
US10280164B2 (en) 2016-09-09 2019-05-07 Incyte Corporation Pyrazolopyridone compounds and uses thereof
US20180072741A1 (en) * 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
WO2018049214A1 (en) * 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
CN110402248B (zh) 2017-03-15 2023-01-06 豪夫迈·罗氏有限公司 作为hpk1抑制剂的氮杂吲哚类
AU2018244935A1 (en) 2017-03-30 2019-08-15 F. Hoffmann-La Roche Ag Naphthyridines as inhibitors of HPK1
EP3601259B1 (en) 2017-03-30 2022-02-23 F. Hoffmann-La Roche AG Isoquinolines as inhibitors of hpk1
US10654825B2 (en) 2017-03-30 2020-05-19 Corvus Pharmaceuticals, Inc. Processes for making triazolo[4,5D] pyramidine derivatives and intermediates thereof
IL276232B2 (en) 2018-03-02 2024-04-01 Otsuka Pharma Co Ltd Pyrazine derivatives, pharmaceutical compositions comprising them and their use for treating diseases
CN108440532A (zh) 2018-03-27 2018-08-24 上海道亦化工科技有限公司 一种苯并吡嗪化合物及其用途和发光器件
MX2020012679A (es) 2018-05-25 2021-02-09 Silverback Therapeutics Inc Compuestos de amino-pirazincarboxamida, conjugados, y usos de los mismos.
CN112243439A (zh) 2018-06-13 2021-01-19 百济神州有限公司 作为hpk1抑制剂的吡咯并[2,3-b]吡啶或吡咯并[2,3-b]吡嗪及其用途
WO2020103896A1 (en) 2018-11-22 2020-05-28 Beigene, Ltd. Pyrrolo[2,3-b]pyridines as hpk1 inhibitor and uses thereof
JP7503851B2 (ja) * 2019-05-06 2024-06-21 アイカーン スクール オブ メディスン アット マウント シナイ Ｈｐｋ１の分解剤としてのヘテロ二官能性化合物
TWI848141B (zh) 2019-07-04 2024-07-11 英屬開曼群島商百濟神州有限公司 及其用途
US12459958B2 (en) 2019-07-17 2025-11-04 Beone Medicines I Gmbh Tricyclic compounds as HPK1 inhibitor and the use thereof
WO2021032148A1 (en) 2019-08-21 2021-02-25 Beigene, Ltd. Aminopyrazine compounds as hpk1 inhibitor and the use thereof
CN112552293A (zh) * 2019-09-25 2021-03-26 珠海宇繁生物科技有限责任公司 一种protac小分子化合物及其应用

Also Published As

Publication number Publication date
CN115073474B (zh) 2024-10-18
EP3994136A4 (en) 2023-06-28
US20220267333A1 (en) 2022-08-25
AU2020299892A1 (en) 2022-01-27
KR20220029690A (ko) 2022-03-08
TWI848141B (zh) 2024-07-11
CN114096536A (zh) 2022-02-25
EP3994136A1 (en) 2022-05-11
CN115028639A (zh) 2022-09-09
JP2022538019A (ja) 2022-08-31
IL289553A (en) 2022-03-01
CO2022001094A2 (es) 2022-04-29
TW202116773A (zh) 2021-05-01
JP7579816B2 (ja) 2024-11-08
MX2022000244A (es) 2022-02-03
WO2021000925A1 (en) 2021-01-07
CN115073474A (zh) 2022-09-20
ZA202110732B (en) 2022-09-28
BR112022000019A2 (pt) 2022-02-22
US12454534B2 (en) 2025-10-28

Similar Documents

Publication Publication Date Title
US12454534B2 (en) Pyrrolo[2,3-b]pyrazines as HPK1 inhibitor and the use thereof
US12516053B2 (en) Bcl-2 inhibitors
US12459958B2 (en) Tricyclic compounds as HPK1 inhibitor and the use thereof
JP7681038B2 (ja) Ｂｔｋ阻害因子とｅ３リガーゼリガンドとのコンジュゲーションによるブルトンチロシンキナーゼ（ｂｔｋ）の分解及び使用方法
WO2020103896A1 (en) Pyrrolo[2,3-b]pyridines as hpk1 inhibitor and uses thereof
WO2021032148A1 (en) Aminopyrazine compounds as hpk1 inhibitor and the use thereof
WO2021180103A1 (en) Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
EP4377318A1 (en) Pyrrolo [2, 3-b] pyrazine-based bifunctional compounds as hpk1 degraders and the use thereof
WO2022143856A1 (en) Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
EP4457230A1 (en) Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
TW202233190A (zh) 作為ＰＩ３Ｋδ抑制劑的咪唑並［１，５－Ａ］吡衍生物
EA046667B1 (ru) ПИРРОЛО[2,3-b]ПИРАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРА HPK1 И ИХ ПРИМЕНЕНИЕ
HK40073633A (en) Pyrrolo [2, 3-b] pyrazines as hpk1 inhibitor and the use thereof
EA050708B1 (ru) Деградация тирозинкиназы брутона (btk) посредством конъюгации ингибиторов btk с лигандом лигазы е3 и способы применения
HK40061243A (en) Pyrrolo [2, 3-b] pyrazines as hpk1 inhibitor and the use thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220729

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20240926

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D11-D131 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (RCE) RECEIVED

Effective date: 20241031

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250124

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D174 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250723

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D148 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (NOA/CNOA) DETERMINED COMPLIANT

Effective date: 20250723

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250723

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250723

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250723

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250723

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260105